Amicus Therapeutics filings document the former public company’s rare-disease biotechnology business, common stock registration, operating results, governance matters, shareholder voting disclosures, material agreements, risk factors, clinical or regulatory updates, and capital-structure information. The filing record includes Form 8-K reports for quarterly results, corporate updates, and material events tied to its business and securities.
Later filings document Amicus Therapeutics’ completed merger, its survival as a wholly owned subsidiary of BioMarin Pharmaceutical Inc., the removal of its common stock from Nasdaq listing through Form 25, and the termination or suspension of Exchange Act reporting obligations through Form 15. These documents record the company’s transition from a Nasdaq-listed issuer to a subsidiary within BioMarin.
Perceptive Advisors and related parties report a 2.4% shared ownership stake in Amicus Therapeutics (FOLD). The filing shows Perceptive Life Sciences Master Fund, Ltd. directly holds 7,412,830 shares and Perceptive Advisors LLC, as manager, and Joseph Edelman, as managing member, report shared voting and dispositive power over those shares. No sole voting or dispositive power is claimed. The ownership percentage is calculated using 308,239,374 shares outstanding. The filing states the position is not held to influence control of the company.